Myriad (MYGN) Issues Response to Supreme Court Decision on Gene Patent
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Join SI Premium – FREE
Myriad Genetics (Nasdaq: MYGN) posted the following response to the U.S. Supreme Court ruling made earlier on its Facebook page:
"The Supreme Court has ruled, vacating some patent claims and upholding others. But we’ve always said the debate was about more than patent claims. It was about human health, and innovation to make sure that cancer tests are accessible and affordable to women who need them.
It’s time now to move on. Under the Affordable Care Act, the BRACAnalysis test is considered preventative, and insurance is required to cover 100 percent of the cost for many women. We offer financial assistance to uninsured patients with the greatest need.
We also want to reach out to patient advocates and the research community. The battle that really matters isn’t in court; it’s the one against cancer."
"The Supreme Court has ruled, vacating some patent claims and upholding others. But we’ve always said the debate was about more than patent claims. It was about human health, and innovation to make sure that cancer tests are accessible and affordable to women who need them.
It’s time now to move on. Under the Affordable Care Act, the BRACAnalysis test is considered preventative, and insurance is required to cover 100 percent of the cost for many women. We offer financial assistance to uninsured patients with the greatest need.
We also want to reach out to patient advocates and the research community. The battle that really matters isn’t in court; it’s the one against cancer."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- FDA grants accelerated approval to Bristol Myers Squibb's Zenbexus
- Sunshine Biopharma gets Canadian approval for generic Enalapril
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Litigation, Management CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
